Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Mol Cell. 2016 Jul 21;63(3):526–538. doi: 10.1016/j.molcel.2016.06.017

Figure 4. Inactivation of the Tumor Suppressor TP53 through CRISPR-Barcoding.

Figure 4

(A) Effects of Nutlin-3 (N3; 10 μM, 7 days) on the TP53-STOP to TP53-WT ratio in MCF7 cells using two distinct sgRNAs (A or B). Mean ± SEM; n = 4 of one representative of three independent experiments. *p < 0.05 (Mann-Whitney test).

(B) Effects of N3 (10 μM; 7 days) or doxorubicin (Dox) on the TP53-STOP to TP53-WT ratio in HCT-116 cells. Mean ± SEM; n = 4 of one representative of three independent experiments.

(C) The cells in (B) were treated for 7 days with KU-55933 (10 μM) and/or Dox (50 nM), and the TP53-STOP to TP53-WT ratio was assessed by qPCR. Mean ± SEM of seven independent experiments.

(D) Effects of KU-55933 (10 μM) and/or N3 (10 μM, 7 days) on the TP53-STOP to TP53-WT ratio in HCT-116 cells. Mean ± SEM; n = 4 of one representative of three independent experiments.

See also Figure S3.